Oliver Bahr

Wuerzburg, BY 97076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro.

Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro.

Journal: Journal of bone oncology

Published: February 16, 2026

Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcification.

Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcification.

Journal: Brain communications

Published: December 12, 2024

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.

Journal: Neuro-oncology

Published: April 14, 2022

Chemotherapy for adult patients with spinal cord gliomas.

Chemotherapy for adult patients with spinal cord gliomas.

Journal: Neuro-oncology practice

Published: July 19, 2021

Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma.

Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma.

Journal: Cancers

Published: June 11, 2021

The High Energy Density Scientific Instrument at the European XFEL.

The High Energy Density Scientific Instrument at the European XFEL.

Journal: Journal of synchrotron radiation

Published: March 06, 2021

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 02, 2020

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.

Journal: Journal of cancer research and clinical oncology

Published: October 06, 2020

Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.

Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.

Journal: Oncology

Published: September 14, 2020

Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032.

Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032.

Journal: Cancers

Published: August 29, 2020

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: May 22, 2020

Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.

Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.

Journal: Neuropathology and applied neurobiology

Published: May 07, 2020

Showing 1-12 of 57

Last Updated: 09/26/2026